Physician profile
Mitchell J Wainwright
NPI 1730138678
$2,201.97
in general payments reported to CMS, 2019-2025
22 companies · $56.69 in 2025
The $56.69 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $547 · 2020: $219 · 2021: $273 · 2022: $718 · 2023: $171 · 2024: $216 · 2025: $56.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $444.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,047.57 | 2019-2024 | Breztri, Farxiga |
| Glaxosmithkline, LLC. | $180.50 | 2019-2023 | Trelegy Ellipta |
| Exact Sciences Corporation | $177.45 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $149.83 | 2019-2023 | Rybelsus, Ozempic |
| Eisai INC. | $108.16 | 2020-2022 | |
| Abbvie INC. | $92.86 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $65.55 | 2019-2022 | |
| Pfizer INC. | $50.87 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $48.31 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.32 | 2019 | |
| Genentech USA, INC. | $38.03 | 2019-2021 | |
| Lilly USA, LLC | $30.06 | 2022-2023 | Jardiance |
| Jazz Pharmaceuticals INC. | $23.99 | 2021 | |
| Edwards Lifesciences Corporation | $23.26 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Astellas Pharma US INC | $19.86 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $19.68 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $17.16 | 2022 | |
| Phadia US INC. | $15.70 | 2024 | Immunocap |
| Otsuka America Pharmaceutical, INC. | $14.96 | 2022 | |
| Antares Pharma, INC. | $14.11 | 2019 | |
| Idorsia Pharmaceuticals US INC | $12.93 | 2023 | Quviviq |
| Adlon Therapeutics L.P. | $11.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Wainwright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.